The Lancet has published full results of a Phase II trial showing the benefit of Lilly’s JAK inhibitor Olumiant in the treatment of global systemic lupus erythematosus (SLE).
News
Lilly links with Anima
Eli Lilly is teaming up with Anima Biotech in an exclusive collaboration to discover and develop translation inhibitors for several protein targets.
AstraZeneca sells Atacand rights to Cheplapharm
AstraZeneca is selling rights to its heart failure and hypertension brand Atacand in Europe, in a move that it says will expand its commercial potential in 28 countries.
FDA staff question efficacy of GSK’s Nucala for COPD
US regulatory advisors are questioning the effectiveness of GlaxoSmithKline’s biologic Nucala as a treatment for patients experiencing a sudden worsening of chronic obstructive pulmonary disorder (COPD).
GSK considers splitting up
GlaxoSmithKline is reportedly considering whether to split its business into a consumer health spin-off and standalone pharmaceutical and vaccines group.
‘Workforce, technology and prevention’ NHS priorities, says Hancock
MP Matt Hancock has unveiled what he sees as “early priorities” in his new role as health and social care secretary: workforce, technology, and prevention.
US approves first-in-class targeted AML therapy
US regulators have approved the first targeted therapy for patients with relapsed or refractory acute myeloid leukemia carrying a certain genetic mutation.
Pfizer bags approval for Neupogen biosimilar
Pfizer’s Neupogen biosimilar Nivestym has been approved by the US Food and Drug Administration and is expected to hit the market at a “significant discount” to its reference drug.
PureTech lifted by news of Roche deal
Shares in UK-based clinical-stage biopharm PureTech Health have been given a boost by news that Roche has signed up to advance its exosome platform technology in a deal potentially worth more than $1 billion.
UK drug advisors recommend rescheduling of medical cannabis
Clinicians in the UK should have the option to prescribe cannabis-derived medicinal products where appropriate, drug experts have concluded, paving the way for laws prohibiting their use to be relaxed.
Allergan, Molecular Partners’ AMD drug non-inferior to Lucentis
Allergan, Molecular Partners’ abicipar has shown non-inferiority to Novartis’ Lucentis but with fewer injections in late-stage trials involving patients with neovascular age-related macular degeneration.
NICE backs radionuclide therapy for some neuroendocrine tumours
A price cut has secured NHS funding for Advanced Accelerator Applications’ Lutathera as a treatment for some neuroendocrine tumours (NETs).
Be recognised for the part you play in targets being met
Ongoing training and development is key to a happy, motivated sales force and now, the PharmaTimes Sales Awards has a category dedicated to the people who make it happen.
Industry shows support for new Medical & Scientific Excellence Awards
News of the inaugural Medical & Scientific Excellence Awards has got the industry talking, with a number of entries already received.
Want to make a difference? Enter the new Charity Challenge
PharmaTimes media is partnering with Bowel Cancer UK and Beating Bowel Cancer to launch a Charity Challenge Award as part of the Communications Team of the Year competition.
